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PRELIMINARY PSYCHOMETRIC VALIDATION  
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Abstract: A i m: The aim of our study was to report preliminary validation data on the EORTC trans-
lated, Polish version of the EORTC QLQ-H&N35 questionnaire to show that this tool is an acceptable 
and psychometrically robust measure to collect HRQoL data in Polish patients with head and neck 
malignancies.
M a t e r i a l s  a n d  M e t h o d s: Patients with histological confirmation of head and neck malignan-
cies were eligible for the study. All patients filled out the Polish version of the EORTC QLQ-H&N35 
module in addition to EORTC QLQ-C30 and a demographic questionnaire. Standardized validity and 
reliability analyses were performed.
R e s u l t s: Fifty-one patients (23 females — 45.1%) were enrolled into the study, with a mean age of 
51.3 ± 12.9 years. Cronbach alpha coefficients, range 0.72–0.85, showed positive internal consistency. 
Satisfactory convergent and discriminant validity in multi-trait scaling analyses was seen.
C o n c l u s i o n s: Basing on the preliminary data from this report, one can say that the Polish version 
of the EORTC QLQ-H&N35 module is a reliable and valid tool for measuring HRQoL in patients with 
head and neck malignancies. However further research is needed to establish the full psychometric 
properties of the described module, especially test-retest and responsiveness over time.
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INTRODUCTION
Worldwide, the incidence and mortality of head and neck neoplasms is increasing 
[1]. Currently, there is a rising concern about the use of health-related quality of 
life (HRQoL) tools to assess this important outcome in oncology. This is especially 
so in patients with head and neck malignancies, because they greatly affect one’s 
well-being [2]. Pretherapeutic staging protocols as well as the management that 
is selected produce dysfunction, disfigurement, and substantial disability even 
after successful curative treatment. Successful medical results often coexist with 
unsatisfactory outcomes from the patient’s point of view [3, 4].
Traditionally, cancer outcomes are measured in terms of overall survival, dis-
ease-free survival, time to disease progression, and other prognosis outcomes. 
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Although these outcomes remain essential, there is general recognition of the 
need to assess the impact of cancer and its treatment on patient’s HRQoL [5]. 
In response to this need, several specific instruments for patients with head and 
neck malignancies have been developed and are commonly used in practice as 
well as in clinical trials, including the European Organization for Research and 
Treatment of Cancer (EORTC) core questionnaire (QLQ-C30) [6–8], its head and 
neck module (QLQ-H&N35) [9], and Functional Assessment of Cancer Therapy 
— Head and Neck (FACT-H&N) [10].
The aim of our study was to report preliminary validation data on the EORTC 
translated, Polish version of the EORTC QLQ-H&N35 questionnaire to show that 
this tool is an acceptable and psychometrically robust measure to collect HRQoL 
data in Polish patients with head and neck malignancies. Our group has previous 
experience in performing this kind of validation studies [11].
MATERIALS AND METHODS
PATIENTS
The patients were recruited prospectively between January 2013 and May 2013 
in three hospitals in Krakow, Poland.
The research protocol was approved by the Jagiellonian University Ethics 
Committee (registry number KBET/7/B/2013). The study has been performed 
in accordance with the ethical standards laid down in the 1964 Declaration of 
Helsinki and its later amendments.
Patients were eligible if they were above 18 years old and had histological 
confirmation of a cancer of the head and neck region. Exclusion criteria included 
lack of consent to participate in the study and inability to understand or complete 
the questionnaires. The patients included were classified into groups based on 
their current Karnofsky Performance Status (KPS) (>80 or ≤80) and being on or 
off treatment [9, 12].
INTERVIEW PROCEDURE
The patients were approached during their visits at the outpatient clinics of the 
participating centres or during their stay at the clinic, and informed about the 
study. They were interviewed only after written informed consent was obtained. 
Each patient completed the Polish version of the EORTC QLQ-C30, the EORTC 
QLQ-H&N35 module and a questionnaire concerning demographic data. Patients 
were provided the measures before undergoing planned treatment. The question-
naires were administered by a medical doctor.
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QUESTIONNAIRES
The EORTC QLQ-C30 is a 30-item questionnaire comprised of a global health 
status, five multi-item functional scales, three multi-item symptom scales and 
six symptom single items. It is translated into over 85 languages [8, 13]. This is 
one of the most frequently used HRQoL measures reported in clinical trials [14].
The EORTC QLQ-H&N35 is a 35-item cancer-specific module composed of 
18 domains, including seven multi-item scales that assess pain (questions 1–4), 
swallowing (questions 5–8), sense problems (questions 13 and 14), speech (ques-
tions 16, 23, 24), social eating (questions 19–22), social contact (questions 18, 
25–28), and sexuality (questions 29 and 30). It also includes 11 single items — 
teeth (no. 9), opening mouth (no. 10), dry mouth (no. 11), sticky saliva (no. 12), 
coughing (no. 15), feeling ill (no. 17), pain killers (no. 31), nutritional supplements 
(no. 32), feeding tube (no. 33), weight loss (no. 34), and weight gain (no. 35). 
All 18 domains of the QLQ-H&N35 have standardized scores ranging from 0 to 
100, with higher scores indicating a greater degree of symptoms (worse HRQoL) 
[4, 5, 9].
All of the EORTC QLQ-C30 and the EORTC QLQ- H&N35 multi-item scales 
and single items are scored on a 1- to 4-point Likert scale (‘not at all’, ‘a little’, 
‘quite a bit’, ‘very much’), apart from items 29 and 30 of the EORTC QLQ-C30, 
which are scored on a 1- to 7-point scale. Detailed information on how to score 
the EORTC questionnaires can be found in the EORTC QLQ-C30 scoring manual 
and its addendum [15]. The questionnaire and the scoring manual were obtained 
from the EORTC Quality of Life Department, upon request of the main author 
of the study.
STATISTICAL ANALYSIS
Several pre-planned standard psychometric tests were conducted, these ap-
proaches can be seen in the EORTC Module Development Guidelines [16, 17].
Scoring of the two measures followed the standard EORTC scoring instruc-
tions. Specifically, scores for single items and multi-item functional and symptom 
scales were calculated by linear transformation of raw scores into a 0–100 score, 
with 100 representing best global health, functional status or worst symptoms 
— depending on the measuring property of each multi-item or single-item scale, 
as described by the EORTC Scoring Manual [15]. To analyse the data descriptive 
statistics (mean, standard deviation, percentage distribution) were used.
Convergent validity was assessed by correlating each item with its own scale. 
Discriminant validity was assessed by correlating each item with any other scale. 
Evidence of item convergent validity was defined as a correlation of 0.40 or greater 
between an item and its own scale (corrected for overlap). A scaling success for 
an item was seen when the correlation between an item and its own scale was 
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significantly higher than its correlation with other scales [18]. Cronbach’s alpha 
coefficient was calculated to assess the internal consistency of the Polish version 
of the EORTC QLQ-H&N35. Internal consistency estimates of a magnitude of 
>0.70 were considered acceptable for group comparisons [18].
Clinical validity was assessed using the Wilcoxon rank sum nonparametric 
test. This assesses if the questionnaire was able to discriminate between sub-
groups of patients differing in clinical status. Known-groups used in this study 
were based on Karnofsky Performance Status (KPS) and being on or off treatment. 
Differences between groups were tested with the Mann–Whitney test.
The significance level was set at p<0.05. Statistical analysis was conducted 
using computer software Statistica 10.0 PL by StatSoft Poland (licensed to the 
Jagiellonian University Medical College).
The acceptability of the QLQ-H&N35 was assessed by the response rate, per-
centage of missing data, assistance and time needed to complete the question-
naire and details of items considered upsetting, confusing or difficult in the 
questionnaire.
RESULTS
PATIENT CHARACTERISTICS AND ACCEPTABILITY
During the 5 month recruitment period a total of 51 patients (23 females — 
45.1%) were enrolled into the study, with a mean age of 51.3 ± 12.9 years. Pa-
tients’ clinical and demographic data are presented in Table 1.
No patients refused to participate in the study. All 51 patients answered both 
the EORTC QLQ-C30 and the EORTC QLQ-H&N35. Only 2.4% of item responses 
were missing.
As much as 43% of the interviewees required assistance completing the ques-
tionnaires. The total time for completion of the questionnaires and interview was 
approximately 19 minutes without assistance and 26 with assistance. No patients 
reported the questions to be upsetting.
Clinical history and physical examination were registered for all patients from 
patient files.
RELIABILITY AND VALIDITY
Reliability, convergent and discriminant validity of QLQ-H&N35 multi-item scales 
are presented in Table 2.
Taking into account the EORTC QLQ-H&N35 its own-scale correlations were 
considered good. All item correlations within their own scales exceeded the 0.40 
criterion, and were correlated higher with their own scale than with the other 
scales. All presented Cronbach alpha values exceeded the 0.7 criterion.
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T a b l e  1
Patients’ clinical and demographic data.
Variable Overall n = 51
Age (mean±SD) 51.3 ± 12.9
Education (%)
Elementary 7 (13.7%)
High School 36 (70.6%)
University 8 (15.7%)
Current working status (%)
Employed 29 (56.9%)
Unemployed 4 (7.8%)
Retired/Pensioner 18 (35.3%)
Living (%)
Alone 8 (15.7%)
With partner or family 41 (80.4%)
With others 2 (3.9%)
Marital status (%)
Married 41 (80.4%)
Divorced 6 (11.8%)
Single 4 (7.8%)
Tumour type (%)
Squamous cell 40 (78.4%)
Adenocarcinoma 11 (21.6%)
Treatment (%)*
Surgery 47 (92.2%)
Chemotherapy 8 (15.7%)
Radiotherapy 14 (27.5%)
Active treatment (%)
Yes 39 (76.5%)
No 12 (23.5%)
Karnofsky Performance Status (%)
>80 36 (70.6%)
≤80 15 (29.4%)
* — more than one treatment option per patient possible; SD — standard deviation.
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Clinical validity assessment by known-group comparison is presented in Ta- 
ble 3. There were significant differences between the groups in most of the EORTC 
QLQ-H&N35 scales and items.
EORTC QLQ-H&N35  
multi-item scale
Convergent validity1 Discriminant  
validity2
Cronbach’s alpha
Pain 0.53–0.69 0.04–0.42 0.81
Swallowing 0.51–0.82 0.08–0.33 0.80
Senses Problems 0.42–0.83 0.02–0.29 0.83
Speech Problems 0.39–0.61 0.14–0.36 0.77
Trouble with Social Eating 0.55–0.71 0.21–0.48 0.85
Trouble with Social Contact 0.33–0.49 0.09–0.22 0.79
Less Sexuality 0.40–0.51 0.01–0.38 0.72
T a b l e  2
Reliability, convergent and discriminant validity of QLQ-H&N35 multi-item scales.
SD — standard deviation
1 — Item-own scale correlation, Spearman correlation coefficient, corrected for overlap
2 — Item-other scale correlation, absolute values displayed, Spearman correlation coefficient
T a b l e  3
EORTC QLQ-H&N35 known group comparison.
EORTC QLQ-H&N35 On Treatment
(n = 39)
Off Treatment
(n =12)
p-value KPS>80
(n = 36)
KPS≤80
(n = 15)
p-value
Multi-item scales
Pain
23.2
(19.4)
24.5
(20.1)
0.84
12.3
(9.3)
28.1
(17.4)
<0.0001
Swallowing
30.6
(18.1)
11.4
(13.2)
0.001
14.7
(12.3)
24.8
(19.0)
0.028
Senses Problems
20.0
(12.5)
17.9
(14.2)
0.62
17.3
(17.1)
19.1
(18.7)
0.74
Speech Problems
28.7
(21.5)
26.3
(18.7)
0.73
15.4
(14.2)
22.3
(21.1)
0.18
Trouble with Social 
Eating
38.4
(27.0)
18.9
(22.4)
0.028
19.4
(18.0)
28.6
(19.7)
0.11
Trouble with Social 
Contact
37.3
(24.6)
16.1
(10.1)
0.006
14.3
(15.6)
26.3
(21.5)
0.030
Less Sexuality
41.7
(23.9)
32.6
(16.6)
0.23
11.4
(10.6)
38.8
(24.9)
<0.0001
Values presented as mean±SD; KPS — Karnofsky Performance Status; SD — standard deviation 
(given in bracktes); Statistically significant values shown in bold.
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DISCUSSION
There is a need to complement classical oncologic outcomes with the use of 
measures of patients’ perception on disease impact and treatment consequences. 
There exists general agreement in literature that measuring HRQoL can achieve 
this aim [4].
The Polish translation of the EORTC QLQ-H&N35 has been with us for the 
past 12 years, and has been used in several studies [19, 20]. However, up-to-
date no proper psychometric validation has been performed. Thus, the aim of 
our study was to report preliminary validation data on the EORTC translated 
Polish version of the EORTC QLQ-H&N35 questionnaire. The full study, aiming to 
deliver complete QLQ-H&N35 psychometric data, is underway. However, to show 
that the QLQ-H&N35 can be used in clinical practice as well as in research, we 
decided to publish this preliminary report.
As new treatment options arise, it is imperative to remember that HRQoL 
should always accompany survival. Thus the need for elegant instruments able 
to accurately assess HRQoL in cancer patients, including those with head and 
neck malignancies. A major drawback of some of the clinical trials that have 
been performed is the fact that they either omitted HRQoL assessment or used 
generic questionnaires to assess HRQoL in specific patient groups. The EORTC 
QLQ-H&N35 seems to perfectly fill the gap.
An important part of our study was that none of the 51 patients approached 
declined to complete the HRQoL forms. Therefore, this can be seen as an indica-
tor of the acceptability of the measures for Polish patients. The fact that almost 
half of the patients required assistance filling in the questionnaires might arise 
from the fact that patients have a need for more direct contact with physicians 
and perceived this study as an opportunity to talk more with their medical pro-
fessionals.
As in the original study by Bjordal et al. [9] construct analysis of the EORTC 
QLQ-H&N35 confirmed the presence of seven distinct multi-item scales, in which 
items within each scale were highly correlated with one another compared with 
items from other scales.
The results of the known-group comparison demonstrated that the EORTC 
QLQ-H&N35 module is able to discriminate between patient subgroups differing 
in clinical status. Overall the obtained results are partially similar to the original 
study [9] and to the study by Carrillo et al. [4].
The main limitation of this study is of course the small number of partici-
pants. However, the full study is underway, and the target sample size is carefully 
planned according to the proposal of Tabachnick and Fidell [21]. It states that 
in order to obtain reliable estimates through multivariate analysis, the number 
of observations should be 5–10 times the number of variables in the model. 
Another limitation is the fact that responsiveness over time and test-retest were 
not analyzed. This will also be calculated, once the target sample size is reached.
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Clinical trials including HRQoL outcomes provide invaluable information con-
cerning the effects of medical management. However, there is controversy about 
whether HRQL data contribute significantly to the clinical decision making pro-
cess. This phenomenon may be due to difficulties in understanding HRQL facts 
by patients or physicians. Recent research is focusing on strategies to increase 
physician and patient understanding of HRQL information, which is usually com-
plex as a result of its multifactorial nature [22].
CONCLUSIONS
In conclusion, basing on the preliminary data from this report, one can say that 
the Polish version of the EORTC QLQ-H&N35 module is a reliable and valid tool 
for measuring HRQoL in patients with head and neck malignancies. However 
further research is needed to establish the full psychometric properties of the 
described module, especially test-retest and responsiveness over time.
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